NeuroSense Therapeutics
NRSN
13 hedge funds and large institutions have $776K invested in NeuroSense Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
171% more capital invested
Capital invested by funds: $286K → $776K (+$490K)
86% more funds holding
Funds holding: 7 → 13 (+6)
1.64% more ownership
Funds ownership: 1.16% → 2.8% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$253K |
| 2 |
Morgan Stanley
New York
|
+$118K |
| 3 |
Jane Street
New York
|
+$74.3K |
| 4 |
HF
HRT Financial
New York
|
+$74K |
| 5 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$101K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$4.71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $305K | +$253K | +219,717 | +641% |
|
|
2
Morgan Stanley
New York
| $123K | +$118K | +102,581 | New |
|
|
3
Jane Street
New York
| $77.6K | +$74.3K | +64,636 | New |
|
|
HF
4
HRT Financial
New York
| $77K | +$74K | +64,390 | New |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| $50.3K | -$4.71K | -4,099 | -9% |
|
|
MIH
6
Meitav Investment House
Bene-Beraq,
Israel
| $48K | – | – | – |
|
|
SWP
7
Stratos Wealth Partners
Beachwood,
Ohio
| $24K | +$23K | +20,000 | New |
|
8
Commonwealth Equity Services
Waltham,
Massachusetts
| $20K | +$4.17K | +3,625 | +29% |
|
9
Geode Capital Management
Boston,
Massachusetts
| $19K | +$4.49K | +3,907 | +33% |
|
|
TSS
10
Two Sigma Securities
New York
| $18K | +$17.3K | +15,017 | New |
|
|
WAM
11
Warberg Asset Management
Winnetka,
Illinois
| $12.8K | +$12.3K | +10,700 | New |
|
12
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
|
SS
13
SBI Securities
Tokyo,
Japan
| $210 | +$201 | +175 | New |
|
|
CF
14
Cantor Fitzgerald
New York
| – | -$101K | -79,492 | Closed |
|
NRSN Hedge Fund Activity: Q4 2024 in Review
13 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q4 2024, worth a combined $776K — up 171% from $286K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NRSN positions and 1 closed out — a net gain of 6 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $253K. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $101K sold.
- 13 institutional investors held NeuroSense Therapeutics (NRSN) as of Q4 2024, up from 7 in Q3 2024.
- Funds reported $776K of NeuroSense Therapeutics stock for Q4 2024, up 171% quarter-over-quarter.
- 7 funds opened new NeuroSense Therapeutics positions in Q4 2024 and 1 closed out, a net change of +6 holders.
- The largest NeuroSense Therapeutics buyer in Q4 2024 was Citadel Advisors, an estimated $253K added.
- The largest NeuroSense Therapeutics seller in Q4 2024 was Cantor Fitzgerald, an estimated $101K sold.
Based on aggregated 13F filings for Q4 2024.